Laila Almeida Viana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Laila Almeida Viana has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- José Osmar Medina-Pestana
Universidade Federal de São Paulo
19 shared publications - Helio Tedesco-Silva
Universidade Federal de Sao Paulo, Brasil
18 shared publications - Marina Pontello Cristelli
Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil
13 shared publications - Lúcio Requião-Moura
Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil
12 shared publications - Renato Demarchi Foresto
Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil
10 shared publications - Daniel Wagner de Castro Lima Santos
University Hospital, Federal University of Maranhão (UFMA), Ebserh, São Luís, Maranhão, Brazil
7 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20250110
Referral for kidney transplantation: a consensus statement from the Brazilian Society of Nephrology
Brazil ranks among the top five countries performing kidney transplants, operating the largest public transplantation system in the world. Nevertheless, the number of procedures performed represents less than 40% of demand, and there are significant regional disparities, with areas of the country reporting very low transplantation activity. Among the potential causes of this scenario are the low frequency of referrals for transplant evaluation and referrals made under inappropriate clinical conditions. In this document, the Brazilian Society of Nephrology aims to compile information supporting the selection of kidney transplantation as a renal replacement therapy. The document also details contraindications and patient care after listing and prioritization, in line with the national context. Our goal is to provide a document that serves as a national reference and contributes to streamlining the referral process for kidney transplantation, making it more frequent and effective, thereby expanding candidates՚ access to this treatment
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20250110
Open AccessReferral for kidney transplantation: a consensus statement from the Brazilian Society of Nephrology
Brazil ranks among the top five countries performing kidney transplants, operating the largest public transplantation system in the world. Nevertheless, the number of procedures performed represents less than 40% of demand, and there are significant regional disparities, with areas of the country reporting very low transplantation activity. Among the potential causes of this scenario are the low frequency of referrals for transplant evaluation and referrals made under inappropriate clinical conditions. In this document, the Brazilian Society of Nephrology aims to compile information supporting the selection of kidney transplantation as a renal replacement therapy. The document also details contraindications and patient care after listing and prioritization, in line with the national context. Our goal is to provide a document that serves as a national reference and contributes to streamlining the referral process for kidney transplantation, making it more frequent and effective, thereby expanding candidates՚ access to this treatment
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Encaminhamento para transplante renal: consenso da Sociedade Brasileira de Nefrologia
Resumo O Brasil está entre os cinco países que mais realizam transplantes renais, operando o maior sistema público de transplantes do mundo. Entretanto, o número de procedimentos realizados representa menos de 40% da demanda, e há grandes disparidades regionais, com áreas do país com atividade transplantadora muito baixa. Entre as potenciais causas para esse cenário estariam a baixa frequência de encaminhamento para avaliação para transplante ou o encaminhamento em condições clínicas inadequadas. A Sociedade Brasileira de Nefrologia propõe, neste documento, reunir as informações que fundamentam a escolha do transplante renal como terapia renal substitutiva, além de detalhar as contraindicações e os cuidados com o paciente após listagem e priorização, alinhados à realidade nacional. Nosso objetivo é fornecer um documento que sirva como referência nacional e contribua para agilizar o encaminhamento ao transplante renal, tornando-o mais frequente e eficaz, ampliando, assim, o acesso dos candidatos a esse tratamento.
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Open AccessEncaminhamento para transplante renal: consenso da Sociedade Brasileira de Nefrologia
Resumo O Brasil está entre os cinco países que mais realizam transplantes renais, operando o maior sistema público de transplantes do mundo. Entretanto, o número de procedimentos realizados representa menos de 40% da demanda, e há grandes disparidades regionais, com áreas do país com atividade transplantadora muito baixa. Entre as potenciais causas para esse cenário estariam a baixa frequência de encaminhamento para avaliação para transplante ou o encaminhamento em condições clínicas inadequadas. A Sociedade Brasileira de Nefrologia propõe, neste documento, reunir as informações que fundamentam a escolha do transplante renal como terapia renal substitutiva, além de detalhar as contraindicações e os cuidados com o paciente após listagem e priorização, alinhados à realidade nacional. Nosso objetivo é fornecer um documento que sirva como referência nacional e contribua para agilizar o encaminhamento ao transplante renal, tornando-o mais frequente e eficaz, ampliando, assim, o acesso dos candidatos a esse tratamento.
- 29 March 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (3) , e14713
Efficacy and safety of single‐dose anti‐thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study
Background: This study aimed to compare the efficacy and safety of basiliximab (BAS) versus a single dose of anti‐thymocyte globulin (r‐ATG) induction therapy in pediatric kidney transplant recipients (KTRs).Methods: This single‐center retrospective comparative cohort study included all pediatric KTRs from May 2013 to April 2018 and followed up to 12 months. In the first period, all recipients received BAS, while from May 2016, a single 3 mg/kg dose of r‐ATG was instituted. Maintenance therapy consisted of a calcineurin inhibitor plus prednisone plus azathioprine or mycophenolate.Results: A total of 227 patients were included (BAS, n = 113; r‐ATG, n = 114). The main combination of immunosuppressive drugs was tacrolimus, prednisone, and azathioprine in both groups (87% vs. 88%, p = .718). Patients receiving r‐ATG showed superior survival‐free of the composite endpoint (acute rejection, graft loss, or death; 76% vs. 61%, p = .003; HR 2.08, 1.29–3.34, p = .003) and lower incidence of biopsy‐proven acute rejection (10% vs. 21%, p = .015). There was no difference in the overall incidence of CMV infection (33% vs. 37%, p = .457), PTLD (1% vs. 3%, p = .309), 30‐day hospital readmissions (24% vs. 23%, p = .847), and kidney function at 12 months (86 ± 29 vs. 84 ± 30 mL/min/1.73m2, p = .614).Conclusions: These data suggest that induction therapy with a single 3 mg/kg dose of r‐ATG is associated with higher efficacy for preventing acute rejection and similar safety profile compared to BAS.
- 29 March 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (3) , e14713
Efficacy and safety of single‐dose anti‐thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study
Background: This study aimed to compare the efficacy and safety of basiliximab (BAS) versus a single dose of anti‐thymocyte globulin (r‐ATG) induction therapy in pediatric kidney transplant recipients (KTRs).Methods: This single‐center retrospective comparative cohort study included all pediatric KTRs from May 2013 to April 2018 and followed up to 12 months. In the first period, all recipients received BAS, while from May 2016, a single 3 mg/kg dose of r‐ATG was instituted. Maintenance therapy consisted of a calcineurin inhibitor plus prednisone plus azathioprine or mycophenolate.Results: A total of 227 patients were included (BAS, n = 113; r‐ATG, n = 114). The main combination of immunosuppressive drugs was tacrolimus, prednisone, and azathioprine in both groups (87% vs. 88%, p = .718). Patients receiving r‐ATG showed superior survival‐free of the composite endpoint (acute rejection, graft loss, or death; 76% vs. 61%, p = .003; HR 2.08, 1.29–3.34, p = .003) and lower incidence of biopsy‐proven acute rejection (10% vs. 21%, p = .015). There was no difference in the overall incidence of CMV infection (33% vs. 37%, p = .457), PTLD (1% vs. 3%, p = .309), 30‐day hospital readmissions (24% vs. 23%, p = .847), and kidney function at 12 months (86 ± 29 vs. 84 ± 30 mL/min/1.73m2, p = .614).Conclusions: These data suggest that induction therapy with a single 3 mg/kg dose of r‐ATG is associated with higher efficacy for preventing acute rejection and similar safety profile compared to BAS.
- 28 March 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (4) , e15298
Assessing the influence of graft loss on 4‐year patient survival after simultaneous pancreas‐kidney transplantation: Kaplan–Meier versus Competing Risk Analysis model
Background: Graft loss increases the risk of patient death after simultaneous pancreas‐kidney (SPK) transplantation. The relative risk of each graft failure is complex due to the influence of several competing events.Methods: This retrospective, single‐center study compared 4‐year patient survival according to the graft status using Kaplan‐Meier (KM) and Competing Risk Analysis (CRA). Patient survival was also assessed according to five eras (Era 1: 2001–2003; Era 2: 2004–2006; Era 3: 2007–2009; Era 4: 2010–2012; Era 5: 2012–2015).Results: Between 2000 and 2015, 432 SPK transplants were performed. Using KM, patient survival was 86.5% for patients without graft loss (n = 333), 93.4% for patients with pancreas graft loss (n = 46), 43.7% for patients with kidney graft loss (n = 16), and 25.4% for patients with pancreas and kidney graft loss (n = 37). Patient survival was underestimated using KM versus CRA methods in patients with pancreas and kidney graft losses (25.4% vs. 36.2%), respectively. Induction with lymphocyte depleting antibodies was associated with 81% reduced risk (HR.19, 95% CI.38–.98, p = .0048), while delayed kidney function (HR 2.94, 95% CI 1.09–7.95, p = .033) and surgical complications (HR 2.94, 95% CI 1.22–7.08, p = .016) were associated with higher risk of death. Four‐year patient survival increased from Era 1 to Era 5 (79% vs. 87.9%, p = .047).Conclusion: In this cohort of patients, kidney graft loss, with or without pancreas graft loss, was associated with higher mortality after SPK transplantation. Compared to CRA, the KM model underestimated survival only among patients with pancreas and kidney graft losses. Patient survival increased over time.
- 28 March 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (4) , e15298
Assessing the influence of graft loss on 4‐year patient survival after simultaneous pancreas‐kidney transplantation: Kaplan–Meier versus Competing Risk Analysis model
Background: Graft loss increases the risk of patient death after simultaneous pancreas‐kidney (SPK) transplantation. The relative risk of each graft failure is complex due to the influence of several competing events.Methods: This retrospective, single‐center study compared 4‐year patient survival according to the graft status using Kaplan‐Meier (KM) and Competing Risk Analysis (CRA). Patient survival was also assessed according to five eras (Era 1: 2001–2003; Era 2: 2004–2006; Era 3: 2007–2009; Era 4: 2010–2012; Era 5: 2012–2015).Results: Between 2000 and 2015, 432 SPK transplants were performed. Using KM, patient survival was 86.5% for patients without graft loss (n = 333), 93.4% for patients with pancreas graft loss (n = 46), 43.7% for patients with kidney graft loss (n = 16), and 25.4% for patients with pancreas and kidney graft loss (n = 37). Patient survival was underestimated using KM versus CRA methods in patients with pancreas and kidney graft losses (25.4% vs. 36.2%), respectively. Induction with lymphocyte depleting antibodies was associated with 81% reduced risk (HR.19, 95% CI.38–.98, p = .0048), while delayed kidney function (HR 2.94, 95% CI 1.09–7.95, p = .033) and surgical complications (HR 2.94, 95% CI 1.22–7.08, p = .016) were associated with higher risk of death. Four‐year patient survival increased from Era 1 to Era 5 (79% vs. 87.9%, p = .047).Conclusion: In this cohort of patients, kidney graft loss, with or without pancreas graft loss, was associated with higher mortality after SPK transplantation. Compared to CRA, the KM model underestimated survival only among patients with pancreas and kidney graft losses. Patient survival increased over time.
- Open Access
- 27 July 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-11
Transition from antigenemia to quantitative nucleic acid amplification testing in cytomegalovirus-seropositive kidney transplant recipients receiving preemptive therapy for cytomegalovirus infection
Due to the high costs, the strategy to reduce the impact of cytomegalovirus (CMV) after kidney transplant (KT) involves preemptive treatment in low and middle-income countries. Thus, this retrospective cohort study compared the performance of antigenemia transitioned to quantitative nucleic acid amplification testing, RT-PCR, in CMV-seropositive KT recipients receiving preemptive treatment as a strategy to prevent CMV infection. Between 2016 and 2018, 363 patients were enrolled and received preemptive treatment based on antigenemia (n = 177) or RT-PCR (n = 186). The primary outcome was CMV disease. Secondarily, the CMV-related events were composed of CMV-infection and disease, which occurred first. There were no differences in 1-year cumulative incidence of CMV-disease (23.7% vs. 19.1%, p = 0.41), CMV-related events (50.8% vs. 44.1%, p = 0.20), neither in time to diagnosis (47.0 vs. 47.0 days) among patients conducted by antigenemia vs. RT-PCR, respectively. The length of CMV first treatment was longer with RT-PCR (20.0 vs. 27.5 days, p < 0.001), while the rate of retreatment was not different (14.7% vs. 11.8%, p = 0.48). In the Cox regression, acute rejection within 30 days was associated with an increased the risk (HR = 2.34; 95% CI = 1.12–4.89; p = 0.024), while each increase of 1 mL/min/1.73 m2 of 30-day eGFR was associated with a 2% reduction risk of CMV-disease (HR = 0.98; 95% CI = 0.97–0.99; p = 0.001). In conclusion, acute rejection and glomerular filtration rate are risk factors for CMV disease, showing comparable performance in the impact of CMV-related events between antigenemia and RT-PCR for preemptive treatment.
- 27 July 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-11
Open AccessTransition from antigenemia to quantitative nucleic acid amplification testing in cytomegalovirus-seropositive kidney transplant recipients receiving preemptive therapy for cytomegalovirus infection
Due to the high costs, the strategy to reduce the impact of cytomegalovirus (CMV) after kidney transplant (KT) involves preemptive treatment in low and middle-income countries. Thus, this retrospective cohort study compared the performance of antigenemia transitioned to quantitative nucleic acid amplification testing, RT-PCR, in CMV-seropositive KT recipients receiving preemptive treatment as a strategy to prevent CMV infection. Between 2016 and 2018, 363 patients were enrolled and received preemptive treatment based on antigenemia (n = 177) or RT-PCR (n = 186). The primary outcome was CMV disease. Secondarily, the CMV-related events were composed of CMV-infection and disease, which occurred first. There were no differences in 1-year cumulative incidence of CMV-disease (23.7% vs. 19.1%, p = 0.41), CMV-related events (50.8% vs. 44.1%, p = 0.20), neither in time to diagnosis (47.0 vs. 47.0 days) among patients conducted by antigenemia vs. RT-PCR, respectively. The length of CMV first treatment was longer with RT-PCR (20.0 vs. 27.5 days, p < 0.001), while the rate of retreatment was not different (14.7% vs. 11.8%, p = 0.48). In the Cox regression, acute rejection within 30 days was associated with an increased the risk (HR = 2.34; 95% CI = 1.12–4.89; p = 0.024), while each increase of 1 mL/min/1.73 m2 of 30-day eGFR was associated with a 2% reduction risk of CMV-disease (HR = 0.98; 95% CI = 0.97–0.99; p = 0.001). In conclusion, acute rejection and glomerular filtration rate are risk factors for CMV disease, showing comparable performance in the impact of CMV-related events between antigenemia and RT-PCR for preemptive treatment.
- Open Access
- 11 July 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (3)
Infección por Klebsiella pneumoniae Productora de Carbapenemasa en Receptores de Transplante Renal
Resumen: Existe una tendencia de aumento del número de casos de infección por bacterias multi-resistentes, teniendo en vista el uso indiscriminado y, a veces, excesivo de antibióticos de amplio espectro en el ambiente hospitalario. Esas infecciones generaron un gran impacto, principalmente en pacientes inmunosuprimidos sometidos al transplante de órganos sólidos. Datos nacionales revelaron un aumento significativo de las tasas de infecciones por bacterias multi-resistentes. El presente estudio tuvo como objetivo evaluar la incidencia y demografía de las infecciones relacionadas a la asistencia a la salud por Klebsiella pneumoniae productora de carbapenemasa (KPC). Este es un estudio observacional, retrospectivo, descriptivo, realizado en centro único (Hospital del Riñón) con evaluación de los resultados de receptores de transplante renal con infección por KPC entre noviembre del 2009 y diciembre del 2015. En nuestro centro, infección de corriente sanguínea por KPC tuvo mayor prevalencia, seguida de infección del aparato urinario. La mortalidad general en 30 días fue del 36%, semejante a la encontrada en la literatura internacional. La infección por bacterias multi-resistentes es una condición clínica grave en pacientes transplantados y constituye un desafío terapéutico.
- 11 July 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (3)
Open AccessInfección por Klebsiella pneumoniae Productora de Carbapenemasa en Receptores de Transplante Renal
Resumen: Existe una tendencia de aumento del número de casos de infección por bacterias multi-resistentes, teniendo en vista el uso indiscriminado y, a veces, excesivo de antibióticos de amplio espectro en el ambiente hospitalario. Esas infecciones generaron un gran impacto, principalmente en pacientes inmunosuprimidos sometidos al transplante de órganos sólidos. Datos nacionales revelaron un aumento significativo de las tasas de infecciones por bacterias multi-resistentes. El presente estudio tuvo como objetivo evaluar la incidencia y demografía de las infecciones relacionadas a la asistencia a la salud por Klebsiella pneumoniae productora de carbapenemasa (KPC). Este es un estudio observacional, retrospectivo, descriptivo, realizado en centro único (Hospital del Riñón) con evaluación de los resultados de receptores de transplante renal con infección por KPC entre noviembre del 2009 y diciembre del 2015. En nuestro centro, infección de corriente sanguínea por KPC tuvo mayor prevalencia, seguida de infección del aparato urinario. La mortalidad general en 30 días fue del 36%, semejante a la encontrada en la literatura internacional. La infección por bacterias multi-resistentes es una condición clínica grave en pacientes transplantados y constituye un desafío terapéutico.
- Open Access
- 11 July 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (3)
Infection by Carbapenemase-Producing Klebsiella pneumoniae in Renal Transplant Recipients
There is a tendency to increase the number of cases of infection by multidrug-resistant bacteria, in view of the indiscriminate and sometimes excessive use of broad-spectrum antibiotics in the hospital environment. These infections have generated great impact, especially in immunosuppressed patients undergoing solid organ transplantation. National data revealed a significant increase in the rates of infections by multidrug-resistant bacteria. The present study aimed to evaluate the incidence and demographics of health care-related infections by carbapenemase-producing K. pneumoniae (KPC). This is an observational, retrospective, descriptive study conducted at a single center (Kidney Hospital) with evaluation of the outcomes of kidney transplant recipients with KPC infection between November 2009 and December 2015. In our center, KPC bloodstream infection had the highest prevalence, followed by urinary tract infection. The overall 30-day mortality was 36%, similar to that found in the international literature. Infection with multidrug-resistant bacteria is a serious clinical condition in transplant patients and poses a therapeutic challenge.
- 11 July 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (3)
Open AccessInfection by Carbapenemase-Producing Klebsiella pneumoniae in Renal Transplant Recipients
There is a tendency to increase the number of cases of infection by multidrug-resistant bacteria, in view of the indiscriminate and sometimes excessive use of broad-spectrum antibiotics in the hospital environment. These infections have generated great impact, especially in immunosuppressed patients undergoing solid organ transplantation. National data revealed a significant increase in the rates of infections by multidrug-resistant bacteria. The present study aimed to evaluate the incidence and demographics of health care-related infections by carbapenemase-producing K. pneumoniae (KPC). This is an observational, retrospective, descriptive study conducted at a single center (Kidney Hospital) with evaluation of the outcomes of kidney transplant recipients with KPC infection between November 2009 and December 2015. In our center, KPC bloodstream infection had the highest prevalence, followed by urinary tract infection. The overall 30-day mortality was 36%, similar to that found in the international literature. Infection with multidrug-resistant bacteria is a serious clinical condition in transplant patients and poses a therapeutic challenge.
- Open Access
- 11 July 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (3)
Infecção por Klebsiella pneumoniae Produtora de Carbapenemase em Receptores de Transplante Renal
Existe tendência de aumento do número de casos de infecção por bactérias multirresistentes, tendo em vista o uso indiscriminado e, por vezes, excessivo de antibióticos de amplo espectro no ambiente hospitalar. Essas infecções geraram grande impacto, principalmente em pacientes imunossuprimidos submetidos ao transplante de órgãos sólidos. Dados nacionais revelaram aumento significativo das taxas de infecções por bactérias multirresistentes. O presente estudo teve como objetivo avaliar a incidência e demografia das infecções relacionadas à assistência à saúde por Klebsiella pneumoniae produtora de carbapenemase (KPC). Este é um estudo observacional, retrospectivo, descritivo, realizado em centro único (Hospital do Rim) com avaliação dos desfechos de receptores de transplante renal com infecção por KPC entre novembro de 2009 e dezembro de 2015. Em nosso centro, infecção de corrente sanguínea por KPC teve maior prevalência, seguida de infecção do trato urinário. A mortalidade geral em 30 dias foi de 36%, semelhante à encontrada na literatura internacional. A infecção por bactérias multirresistentes é uma condição clínica grave em pacientes transplantados e constitui um desafio terapêutico.
- 11 July 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (3)
Open AccessInfecção por Klebsiella pneumoniae Produtora de Carbapenemase em Receptores de Transplante Renal
Existe tendência de aumento do número de casos de infecção por bactérias multirresistentes, tendo em vista o uso indiscriminado e, por vezes, excessivo de antibióticos de amplo espectro no ambiente hospitalar. Essas infecções geraram grande impacto, principalmente em pacientes imunossuprimidos submetidos ao transplante de órgãos sólidos. Dados nacionais revelaram aumento significativo das taxas de infecções por bactérias multirresistentes. O presente estudo teve como objetivo avaliar a incidência e demografia das infecções relacionadas à assistência à saúde por Klebsiella pneumoniae produtora de carbapenemase (KPC). Este é um estudo observacional, retrospectivo, descritivo, realizado em centro único (Hospital do Rim) com avaliação dos desfechos de receptores de transplante renal com infecção por KPC entre novembro de 2009 e dezembro de 2015. Em nosso centro, infecção de corrente sanguínea por KPC teve maior prevalência, seguida de infecção do trato urinário. A mortalidade geral em 30 dias foi de 36%, semelhante à encontrada na literatura internacional. A infecção por bactérias multirresistentes é uma condição clínica grave em pacientes transplantados e constitui um desafio terapêutico.
- Open Access
- 9 February 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 44 (3) , 383-394
Predictive ability of severity scores and outcomes for mortality in kidney transplant recipients with coronavirus disease 2019 admitted to the intensive care unit: results from a Brazilian single-center cohort study
Background: the predictive ability of severity scores for mortality in patients admitted to intensive care units is not well-known among kidney transplanted (KT) patients, especially those diagnosed with coronavirus disease 2019 (COVID-19). The purpose of the present study was to evaluate the predictive ability of severity scores for mortality in KT recipients. Methods: 51 KT recipients with COVID-19 diagnosis were enrolled. The performance of the SOFA, SAPS 3, and APACHE IV tools in predicting mortality after COVID-19 was compared by the area under the ROC curve (AUC-ROC) and univariate Cox regression analysis was performed. Results: The 90-day cumulative incidence of death was 63.4%. Only APACHE IV score differed between survivors and nonsurvivors: 91.2±18.3 vs. 106.5±26.3, P = 0.03. The AUC- ROC of APACHE IV for predicting death was 0.706 (P = 0.04) and 0.656 (P = 0.06) at 7 and 90 days, respectively. Receiving a kidney from a deceased donor (HR = 3.16; P = 0.03), troponin levels at admission (HR for each ng/mL = 1.001; P = 0.03), APACHE IV score (HR for each 1 point = 1.02; P = 0.01), mechanical ventilation (MV) requirement (HR = 3.04; P = 0.002) and vasopressor use on the first day after ICU admission (HR = 3.85; P < 0.001) were associated with the 90-day mortality in the univariate analysis. Conclusion: KT recipients had high mortality, which was associated with type of donor, troponin levels, early use of vasopressors, and MV requirement. The other traditional severity scores investigated could not predict mortality.
- 9 February 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 44 (3) , 383-394
Open AccessPredictive ability of severity scores and outcomes for mortality in kidney transplant recipients with coronavirus disease 2019 admitted to the intensive care unit: results from a Brazilian single-center cohort study
Background: the predictive ability of severity scores for mortality in patients admitted to intensive care units is not well-known among kidney transplanted (KT) patients, especially those diagnosed with coronavirus disease 2019 (COVID-19). The purpose of the present study was to evaluate the predictive ability of severity scores for mortality in KT recipients. Methods: 51 KT recipients with COVID-19 diagnosis were enrolled. The performance of the SOFA, SAPS 3, and APACHE IV tools in predicting mortality after COVID-19 was compared by the area under the ROC curve (AUC-ROC) and univariate Cox regression analysis was performed. Results: The 90-day cumulative incidence of death was 63.4%. Only APACHE IV score differed between survivors and nonsurvivors: 91.2±18.3 vs. 106.5±26.3, P = 0.03. The AUC- ROC of APACHE IV for predicting death was 0.706 (P = 0.04) and 0.656 (P = 0.06) at 7 and 90 days, respectively. Receiving a kidney from a deceased donor (HR = 3.16; P = 0.03), troponin levels at admission (HR for each ng/mL = 1.001; P = 0.03), APACHE IV score (HR for each 1 point = 1.02; P = 0.01), mechanical ventilation (MV) requirement (HR = 3.04; P = 0.002) and vasopressor use on the first day after ICU admission (HR = 3.85; P < 0.001) were associated with the 90-day mortality in the univariate analysis. Conclusion: KT recipients had high mortality, which was associated with type of donor, troponin levels, early use of vasopressors, and MV requirement. The other traditional severity scores investigated could not predict mortality.
- Open Access
- 20 August 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (2) , 610-625
Development and validation of a simple web-based tool for early prediction of COVID-19-associated death in kidney transplant recipients
- 20 August 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (2) , 610-625
Open AccessDevelopment and validation of a simple web-based tool for early prediction of COVID-19-associated death in kidney transplant recipients